Company Profile

Company Overview

Relay Therapeutics is a new breed of company at the intersection of computation and biotechnology that is committed to creating medicines that will have a transformative impact on patients.

We combine unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology. This integration illuminates – for the first time – the full mobility of a protein and provides key insights into how the dynamic nature of a protein’s conformation regulates function. The team at Relay is putting this principle into practice, with the aim of accelerating the development of medicines that will make a transformative difference in patients’ lives. We don't just stare hard problems in the face. We go out looking for them. Are you energized by attempting to do the impossible? We're looking for you.

At Relay Tx, our team is energized by the ultimate collaboration across each of our drug discovery disciplines. Putting protein motion at the heart of drug discovery is a challenge, but we are confident that our team’s dedication and urgency will create opportunities that deeply impact the lives of the patients. Our initial programs are focused on developing therapeutics in oncology.

Relay Therapeutics is a private company launched in 2016 with financing from Third Rock Ventures and an affiliate of D. E. Shaw Research. To date the company has raised $520M from investors including Third Rock Ventures, SoftBank Vision Fund, GV, Casdin Capital, BVF Partners, EcoR1 Capital, Foresite Capital, Perceptive Advisors, Tavistock Group and an affiliate of D.E. Shaw Research.